tbuckley/cabot-search huggingface dataset:
Abstract 1413: Interleukin 13 Exerts Anti-appoptotic Effects On Hypoxic Cardiomyocytes Through Pi3 Kinase In The Absence Of Hypertrophic Effects
Authors: Jochen Poeling, Thomas Kubin, Wolfgang Rees, Stefan Hein, Gil-Jin Shim, Henning Warnecke, Thomas Braun
Journal: Circulation (2007)

Objectives: Recent research has focussed on anti-inflammatory cytokines (a-ICs) as cardio-protective agents. A-ICs were mainly considered in the context of inhibition of secretion of pro-ICs such as tumour necrosis factor-α and with the exception of transforming growth factor β little is known about direct effects of a-ICs on cardiomyocytes (CMC). Methods: To clarify a direct functional relationship of a-ICs we evaluated effects of interleukin-4, -10 and -13 on cultured CMC by planimetry, confocal microscopy (CF), protein synthesis determination (PS), 2DE-analysis (2DE), mass spectrometry and Western blotting. Intracellular pathways were analysed with specific chemical inhibitors. Anti-appoptotic effects were evaluated by determinating the cell number, cleaved caspase 3 (cC3) and PARP (cP) under 2% O 2 . Untreated cell lines (unCO) or leukemia inhibitory factor (LIF) treated CMC served as controls. Findings: In contrast to Il-13 we did not detect effects of Il-4 and Il-10 on CMC. Il-13 treated CMC showed a 40% (p&lt;0.01) increased viability over unCO under normoxic and 65% (p&lt;0.01) under hypoxic conditions after 4d and 12h, respectively. Under hypoxia antiapoptotic effects were visible in 60% reduction of cC3 (60%; p&lt;0.05) and cP (40%; p&lt;0.05). Using a battery of more than 300 phospho-specific antibodies we found that phosphorylation of Akt (5-fold, p&lt;0.01) was the predominant activated pathway but we found also mild increases in P-MEK1/2 (1.7-fold). The antiapoptotic effects and Akt activation were abolished in the presence of the PI3 kinase inhibitor (20μM) LY294002 (p&lt;0.01) but not in the presence of the MEK1/2 inhibitor (5μM) UO126. In contrast we did not find any significant morphological changes of CMC in the presence of Il-13 neither in the protein composition of structural proteins (2DE, CF), nor increases in PS nor changes in cell surface area, width and length opposing hypertrophic responses visible after LIF treatment. Conclusions: These findings indicate that Il-13 can directly support myocyte function in addition to its inactivation of immune cells. Our results and the existence of a Il-13 receptor in the heart altogether throws light on Il-13 as a promising therapeutical target.
Editorial Board
Authors: Bruce Thiers, Dirk Elston, Detra Davis, Kenneth Katz, Jack Lesher, Mary Spellman, Jeffrey Weinberg, Dermatologic Surgery, Clifford Perlis, Julie Prendiville, Frcpc Dermatopathology, John Maize, Social Media, Emily Altman, Robert Dellavalle, J Smith, Editors Emeritus, Richard Dobson, Jeffrey Bernhard, Calvin Mccall, Brett Sloan, James Solomon, Stephen Tyring, George Hruza, Pediatric Dermatology, Kelly Cordoro, Dermatopathology Carlson, Tammie Ferringer, Cyberdermatology Consultant, Daniel Siegel, Clara Kim, Bryan Anderson, Salvador Arias-Santiago, Trisha Beute, John Binhlam, Diana Bolotin, Markus Braun-Falco, Nooshin Brinster, Patrick Carrington, Zoe Draelos, Nananamibia Duffy, Laura Ferris, David Fivenson, Joel Gelfand, Camille Introcaso, Nathaniel Jellinek, Jonathan Kantor, Matthew Kanzler, Kevin Kia, Nikki Levin, Kenneth Linden, Jason Lott, Omar Lupi, J Acad, Dermatol November
Journal: Journal of the American Academy of Dermatology (2015)
Error in Table 2
Authors: Christine Jones
Journal: JAMA Internal Medicine (2019)

George F. Sawaya, MD; Erinn Sanstead, MPH; Fernando Alarid-Escudero, PhD; Karen Smith-McCune, MD, PhD; Steven E. Gregorich, PhD; Michael J. Silverberg, PhD, MPH; Wendy Leyden, MPH; Megan J. Huchko, MD, MPH; Miriam Kuppermann, PhD, MPH; Shalini Kulasingam, PhD
MNGI-05. DEVELOPMENT AND VALIDATION OF A DNA METHYLOME-BASED PREDICTOR OF MENINGIOMA RECURRENCE AND MENINGIOMA RECURRENCE SCORE
Authors: Farshad Nassiri, Yasin Mamatjan, Suganth Suppiah, Jetan Badhiwala, Sheila Mansouri, Shirin Karimi, Patrick Harter, Peter Baumgarten, Michael Weller, Matthias Preusser, Christel Herold-Mende, Felix Sahm, Andreas von Deimling, Gelareh Zadeh, Kenneth Aldape
Journal: Neuro-Oncology (2018)

The greatest clinical challenge faced in meningioma is the inability to predict recurrence for individual patients, limiting the ability to select patients who would benefit from adjuvant radiation therapy to prevent recurrence. Therefore, in this multi-center cohort study, we utilized global epigenome DNA methylation profiles from human meningioma samples to generate and validate a methylome-based predictor of recurrence-free survival (RFS) and a meningioma recurrence score. Cox modeling of individual probes was used for feature selection in a training set (N=228 patients) which was then applied to two independent validation sets (N=54; N=140 patients). Gene-expression analysis was correlated to DNA methylation profiles using two published microarray datasets (GSE16581;GSE9438). Finally, penalized Cox modeling was used to generate a 5-year meningioma recurrence score based on a nomogram that integrated our validated methylome-based predictor with established clinical factors. The methlyome-based predictor was independently associated with RFS in each of the two validation sets, after adjusting for tumor grade and extent of resection (EOR; HR 4.0, 95%CI 1.4 – 11.5, P = 0.01 and HR 2.3, 95%CI 1.4 – 3.8, P=0.002). Using a 5-year RFS metric, the methylome-based predictor performed favourably compared to a grade-based predictor in both validation cohorts (ΔAUC =15%; ΔAUC=12%). Functional annotation of the included probes implicated the homeobox gene family. A nomogram constructed using the validated methylome-predictor with WHO grade and EOR demonstrated greater predictive performance than a nomogram using clinical factors alone (ΔAUC = 7.7%) and resulted in two different risk groups with distinct recurrence patterns (P <0.001). The methylome-based predictor and meningioma recurrence score developed and validated in this study provide important prognostic information not captured by established clinical factors and represent the first combined molecular and clinical prognostic tool that is individualized for patients with meningiomas, and hence an advance towards precision medicine in meningiomas
Parental Occupation and Childhood Cancer: Review of Epidemiologic Studies
Authors: David A. Savitz, Jianhua Chen
Journal: Environmental Health Perspectives (1990)

Parental occupational exposures might affect childhood cancer in the offspring through genetic changes in the ovum or sperm or through transplacental carcinogenesis. The 24 published epidemiologic studies of this association have all used case-control designs, with controls generally selected from birth certificates or from general population sampling. Occupational exposures were inferred from job titles on birth certificates or through interviews. A large number of occupation-cancer associations have been reported, many of which were not addressed or not confirmed in other studies. Several associations have been found with consistency: paternal exposures in hydrocarbon-associated occupations, the petroleum and chemical industries, and especially paint exposures have been associated with brain cancer; paint exposures have also been linked to leukemias. Maternal exposures have received much less attention, but studies have yielded strongly suggestive results linking a variety of occupational exposures to leukemia and brain cancer. The primary limitations in this literature are the inaccuracy inherent in assigning exposure based on job title alone and imprecision due to limited study size. Although no etiologic associations have been firmly established by these studies, the public health concerns and suggestive data warrant continued research.
Archiv für Geschwulstforschung, Dresden
Journal: JAMA (1964)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
A multicenter, randomized phase II study of second-line maximum androgen blockade with an alternative antiandrogen combined with tegafur-uracil (UFT) for prostate cancer with relapse after initial hormonal therapy.
Authors: H. Kanayama, M. Takahashi, T. Fukumori, R. Kawabata, A. Kawano, Y. Murakami, Y. Sutou, T. Inai, S. Akazawa, T. Hamao
Journal: Journal of Clinical Oncology (2010)

e15030 Background: Management of advanced prostate cancer with relapse after initial hormonal therapy is still challenging. Some reports have shown that the second line maximum androgen blockade with an alternative antiandrogen (2nd MAB) is still effective. However 2nd MAB has relatively low PSA response rate of about 35%. We sought to determine whether the combination therapy of 2nd MAB and UFT would be even more effective than 2nd MAB alone and also to correlate the treatment effect with the thymidylate synthase (TS) mRNA expression levels. Methods: Patients who were histologically confirmed with prostate cancer and relapsed after LH-RH analogue alone or MAB were included in this study. ECOG performance status was 0-2. All patients were randomly allocated into two groups, 2nd MAB (group A) or 2nd MAB combined with UFT orally at a dose of 260 mg/m2/day (group B) until recurrence. The primary endpoint was PSA response rate (effectiveness defined as > 50% decrease of PSA) and one of the secondary endpoint was PFS. TS mRNA expression levels in formalin fixed paraffin embedded biopsy specimens were measured by RT-PCR method. Results: Fifty three patients were enrolled in this study and clinical data for 38 patients were available so far. Median age was 76 (47-89) years. There were no severe AEs in both groups. PSA response rate in group B (70.6%) tended to be higher than that in group A (36.8%) (p=0.0543). Group B (16.1 months) had significantly longer median PFS than group A (6.4 months) (p=0.0028). Biopsy samples were available in 33 patients for TS mRNA measurement. Interestingly, among patients who were treated with 2nd MAB combined with UFT, those with low TS (88%) had higher PSA response rate than those with high TS (57%). Conclusions: After relapse with initial hormonal therapy, 2nd MAB along with UFT is an effective and well-tolerated treatment option before introducing docetaxel, especially for elderly patients with prostate cancer with low TS expression level. No significant financial relationships to disclose.
Diagnosis of Whooping Cough: Comparison of Serological Tests with Isolation of Bordetella Pertussis
Journal: BMJ (1970)

Antibody titres for Bordetella pertussis in paired sera from 223 children with suspected whooping cough showed good correlation by complement fixation and agglutination techniques. The patient's age was related to serological responses and in a different way to B. pertussis isolations: in 73 children under 6 months of age B. pertussis was isolated from nasopharyngeal secretions in 42% and serological findings were positive in 19%; in 11 patients over 1 year of age serological tests were positive in 65% and cultures in 19%. B. pertussis was isolated from 59 out of 210 patients, while rising antibody titres were found in a further 43 from whom no isolations were made; thus 102 (49%) out of 210 showed evidence of infection with B. pertussis. Serotype 1,3 was the commonest serotype isolated from both immunized and unimmunized children. Previous immunization appeared to reduce the chances of isolating B. pertussis.
Pneumococcal pneumonia in hospitalized patients. Clinical and radiological presentations
Authors: S. Ort
Journal: JAMA (1983)

The clinical and radiological features of pneumococcal pneumonia were studied in 94 hospitalized patients. Fifty-seven (61%) had a bronchopneumonic pattern on roentgenogram, and 37 (39%), a lobar pattern. Eighty-two (87%) of the patients in both roentgenographic classifications had one or more underlying disease states. There was no difference in the frequency of heart disease, diabetes, chronic pulmonary disease, or malignancy between the two categories. Sputum Gram's stains were also similar in both patterns. Twenty (54%) of the 37 patients with the lobar pattern were bacteremic compared with only five (9%) of the 57 patients with the bronchopneumonic pattern; all five patients with bronchopneumonia and bacteremia had an associated malignancy. Although a lobar pattern is usually emphasized in the diagnosis of pneumococcal pneumonia, this study showed that the majority of patients hospitalized with pneumococcal pneumonia had a roentgenographic bronchopneumonic pattern rather than the classic lobar pattern. Thus, patients with the bronchopneumonic pneumococcal pneumonia pattern may be underdiagnosed. The implications are important both for treatment and for epidemiologic data used in the selection of pneumococcal types for prophylactic vaccines. (<i>JAMA</i>1983;249:214-218)
European Perspectives
Journal: Circulation (2011)

He says, "The most important studies from my point of view are the Nordic Diltiazem [NORDIL] trial, the first trial of a calcium channel blocker in hypertension 1 ; the Losartan Intervention For Endpoint [LIFE] trial, the first trial of an angiotensin receptor blocker in hypertension and the first, and so far the only, trial in patients with hypertensive heart disease 2 ; the Valsartan Antihypertensive Long-Term Use Evaluation [VALUE], the first, and so far the only, comparison of a calcium channel blocker and a renin-angiotensinaldosterone system inhibitor in hypertension 3 ; and the Anglo-Scandinavian Cardiac Outcomes Trial [ASCOT], the first successful statin trial in hypertension, 4 and the first trial of a calcium channel blocker and renin-angiotensinaldosterone system inhibitor combination in hypertension." 5ther important trials involving Professor Kjeldsen include the Avoiding Cardiovascular Events Through Combination Therapy in Patients Living With Systolic Hypertension (ACCOMPLISH) trial, which was the first trial to compare the cardiovascular outcomes of initial On other pages...
Oxaliplatin, irinotecan, and bevacizumab followed by docetaxel and bevacizumab in inoperable gastric cancer: First results of a multicenter phase II trial (AGMT Gastric-3) of the Arbeitsgemeinschaft Medikamentoese Tumortherapie (AGMT).
Authors: E. Woell, F. Keil, J. Thaler, B. Gruenberger, M. Hejna, W. Eisterer, M. A. Fridrik, F. Romeder, R. Greil
Journal: Journal of Clinical Oncology (2011)

e14502 Background: Patients (pts.) with advanced gastric cancer still have only limited treatment options. In our previous phase II trials (AGMT-Gastric-1 and AGMT Gastric-2) we could show efficacy of oxaliplatin and irinotecan as well as oxaliplatin, irinotecan and cetuximab.Time to progression however was short suggesting resistancy to chemotherapy. Therefore in the current Gastric-3 trial we investigate sequential chemotherapy combined with bevacizumab. Methods: Oxaliplatin 85 mg/m2 biweekly (q2w) and irinotecan 125 mg/m2 q2w were administered for the first three months followed by docetaxel 50mg/m2 q2w for three months. Chemotherapy is combined with bevacizumab 5 mg/kg q2w until progression. Inclusion of 40 patients with histological proven unresectable and/or metastatic gastric adenocarcinoma is planned in a first line setting. For this abstract 19 patients have been evaluated: Median age: 65 years (range 26-81 years), PS 0: 13 patients, PS 1: 5 patients (1 patient not available), single metastatic site: 13 patients, multiple metastases: 6 patients. Results: Frequently reported adverse events (more than 20% of pts.) were predominantly grade 1 or 2 (90%) and included nausea (9/19), polyneuropathy (8/19), diarrhoea (8/19), fatigue (7/19), asthenia (4/19) and vomiting (4/19). There were 4 adverse events (AEs) grade 4, all in one patient, three consecutive cases of neutropenia and one leucopenia. There were 8 AEs grade 3 in 6 patients including thrombocytopenia, anemia, leucopenia, neutropenia, hydronephrosis, candidiasis, duodenitis with diarrhea and haematemesis (one case each). Conclusions: The combination of oxaliplatin and irinotecan with bevacizumab followed by docetaxel with bevacizumab is feasible and safe in advanced gastric cancer. Updated results will be presented during the meeting.
The treatment of cor pulmonale
Authors: J. W. Wynne
Journal: JAMA (1978)

COR PULMONALE is broadly defined as alteration of the structure or function of the right ventricle as a result of disease or dysfunction of the lungs.<sup>1,2</sup>The constant feature of this disorder is pulmonary hypertension in response to which the right ventricle may dilate, hypertrophy, or subsequently fail. Chronic obstructive lung disease (COLD) is the most common cause of cor pulmonale, but it also may be seen with many other lung diseases, in persons with normal lung function residing at high altitudes, or as a result of hypoventilation, as in the syndromes of primary alveolar hypoventilation or sleep apnea. <h3>PATHOPHYSIOLOGY</h3> The modern approach to the therapy of cor pulmonale is based on extensive investigation into the mechanisms that cause pulmonary hypertension and into the physiological changes that accompany it. Several excellent reviews have summarized this wealth of information.<sup>1-3</sup>It is generally agreed that the most potent stimulus to
Die Säuglingsernährung: Eine Anleitung für Ärzte und Studierende.
Journal: JAMA (1930)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Biochimica et Biophysica Acta, Amsterdam
Journal: JAMA (1969)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
A Gene Expression Signature of Benign Monoclonal Gammopathy Evident in Multiple Myeloma Is Linked to Good Prognosis.
Authors: Fenghuang Zhan, Bart Barlogie, Varant Arzoumanian, Yongsheng Huang, Klaus Hollmig, Mauricio Pineda-Roman, Guido Tricot, Frits van Rhee, Maurizio Zangari, Madhav Dhodapkar, John D. Shaughnessy
Journal: Blood (2006)